IL6R and COVID-19: Although the National Institutes of Health guidelines recommend the use of tocilizumab, a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R), for the treatment of critical COVID-19 (7), there have been conflicting results relating to the efficacy of this drug (8–10).